Silence Therapeutics delivered a solid QQ4 2024 performance driven by collaboration revenue and a strengthened pipeline. In the fourth quarter, revenue stood at $24.33 million, contributing to a full-year 2024 revenue of $43.30 million, up from $31.6 million in 2023. The company posted a quarterly gross margin of approximately 93.4% (Q4 2024 gross profit of $22.72 million on revenue of $24.33 million), reflecting a revenue mix weighted toward collaborations rather than traditional product sales. Despite an operating loss for the year, Silence generated meaningful EBITDA in Q4 and finished the year with a robust liquidity position: cash and short-term investments totaled $147.3 million at year-end 2024, and net cash after forex effects improved materially to a net cash position (net debt) of approximately negative $121.2 million.
Management underscored strategic flexibility by extending the cash runway into 2027 through a disciplined stance: zerlasiran Phase 3 will only commence after securing a partner, which preserves optionality to fund the portfolio’s broader value drivers (divesiran, SLN548, extrahepatic targets) while maintaining optionality for collaboration upside. The company reiterated a 2025 focus on rare diseases and first-in-class/best-in-class siRNA programs, with SANRECO Phase 2 enrollment targeted by year-end and SLN548 entering a Phase 1 healthy volunteer study in H2 2025. Divesiran continues to demonstrate compelling Phase 1 results (eliminating phlebotomy in well-controlled PV patients) and is advancing toward Phase 2 enrollment, with Orphan Drug Designation and Fast Track status supporting PV expansion potential. Overall, Silence remains a development-stage company with a clear path to value through its partnerships and pipeline milestones, albeit with elevated R&D burn and execution risk around partnering zerlasiran and potential regulatory/clinical hurdles.
From a quantitative standpoint, the full-year 2024 net loss narrowed modestly to approximately $45.3 million from $54.2 million in 2023, driven by higher collaboration revenues (notably from AstraZeneca) offset by rising R&D expense as proprietary programs progress. The company reported $4.5 million of other income and approximately $13.7 million of UK R&D tax credits in 2024. The investor-friendly cash runway extension, coupled with ongoing strategic collaboration initiatives, positions Silence to navigate near-term milestones while funding long-term pipeline value creation. Investors should monitor partner qualification and timing for zerlasiran, the pace of SANRECO Phase 2 enrollment, regulatory milestones for divesiran, and the progression of SLN548 and extrahepatic programs as key drivers of optionality and long-term upside.